CYP3A4 and Hypercalciuria: Another pharmaceutical therapeutic option is the enzymatic induction of CYP3A4 by rifampicin, which has been successfully used in patients with CYP24A1 mutations to diminish hypercalcemia and hypercalciuria [23].